In line with its strategy, the acquisition expands Medivir’s commercial activities in the Nordic countries and creates the platform for the expected launch and commercialization of TMC435.
BioPhausia gives Medivir complementary competencies in regulatory affairs, logistics, distribution, marketing, sales and quality assurance, and a local presence in Sweden, Denmark and Finland.
BioPhausia portfolio of pharmaceuticals includes disease areas such as gastrointestinal, central nervous system (CNS) and emergency medicine, and includes, inter alia, products such as Mollipect and Citodon.
Medivir CEO Ron Long said they are delighted to welcome BioPhausia team to Medivir and skills that they bring will advance commercial capabilities to realize value from TMC435, a once-daily, protease inhibitor in Phase 3 development for hepatitis C.
Medivir will become 90% shareholder if BioPhausia accepts the offer.